First, thanks to BTH for answering my question. As to the slight pullback today, I think we all expected it. Should continue to run until ASCO. After that, hopefully management has some good news to announce such as the ponatinib/asia deal to offset the usual post ASCO dropoff. If there is a drop, I dont think Ariad will be as affected as most as there are too many near term catalysts yet to come and I think any substantial weakness will be very short lived if it occurs at all afer ASCO. Would like to see the deal for Ponainib right after ASCO to add to the momentum. Any knowledge of a fourth molecule... I'm sure Ariad's research team is not resting on its laurels and is hard at work coming up with the next silver bullet.
News 
Market Data 
Discover 
AI
